Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIEMA immunogenicity study in preterm infants
NL-OMON21928Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of diphtheria, tetanus, and acellular pertussis vaccine, trivalent inactivated polio vaccine, haemophilus influenzae type b vaccine, Hepatitis B vaccine, pneumococcal conjugate vaccine and 1 more in Infectious disease (3 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Seroconversion rates at 5 and 12 months and Absolute antibody levels against routine vaccine components. Started Oct 2015; status: active, not recruiting.
02
Drugs
diphtheria, tetanus, and acellular pertussis vaccinetrivalent inactivated polio vaccinehaemophilus influenzae type b vaccineHepatitis B vaccinepneumococcal conjugate vaccine
03
Conditions
Infectious disease
Beyond the preview
Go deeper on NL-OMON21928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21928.